About CANMAT           Help & Resources           Clinical Research          CME         
 

CME
Treating Depressive Disorders
 
Dysthymia
Level of Evidence Place in Therapy Medication Usual Daily Dose1 3 Cost per
Day2
Level I Evidence and generally tolerable side effect/safety profile. 1st choice FLUOXETINE
(Prozac) 		20-40 mg $1.08-2.16
FLUVOXAMINE
(Luvox) 		100-200 mg $0.99-1.98
SERTRALINE
(Zoloft) 		50-150 mg $1.60-3.35
MOCLOBEMIDE
(Manerix) 		450-600 mg $1.22-2.28
Level II evidence or Level I evidence but less tolerable side effect/safety profile. 2nd choice VENLAFAXINE
(Effexor) 		75-225 mg $1.56-3.21
DESIPRAMINE4
(Norpramin) 		100-250 mg $0.82-2.06
IMIPRAMINE
(Tofranil) 		100-250 mg $0.04-0.09
Level III evidence or Level I/II evidence and significantly less tolerable side effect/safety profile. 3rd choice DOXEPINE
(Sinequan) 		100-250 mg $0.63-1.57
PHENELZINE5
(Nardil) 		30-75 mg $0.60-1.50

NOTE: Non-responding patients should be switched to an alternative 1st choice agent prior to attempting a 2nd choice antidepressant.

 

1. Usual daily doses are provided unless otherwise stated. Consult the drug monograph for details on age and condition specific dosing.
2. Approximate costs were derived from the ODB formulary (#36) or manufacturers' price lists and do not include professional fees or markups.
3. Some patients respond to lower than usual daily doses.
4. May have fewer anticholinergic side effects than other TCAs.
5. Food and drug restrictions apply. Two-week washout required after discontinuation.

From: CANMAT - Guidelines for the Diagnosis and Pharmacological Treatment of Depression (1st Edition Rev., 1999) Page 30.

Back to Managing Depressive Disorders - (Selections from: CANMAT - Guidelines for the Diagnosis and Pharmacological Treatment of Depression [1st Edition Rev., 1999])

 

 


Over one million Canadians suffer from some form of depressive illness.